Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

SHOCKING: Large patient population is key driver for bright minds growth - What They Never Told You

Epilepsy drugs

BTIG initiated coverage on Bright Minds Biosciences Inc. (NASDAQ:DRUG), a clinical-stage company focused on neurological and psychiatric disorders.

Investment in Bright Minds is based on the expectation that BMB-101 will effectively and precisely treat absence seizures without unacceptable toxicities.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.